Remote Irritable Bowel Syndrome (IBS) Monitoring Market Report 2026

The remote irritable bowel syndrome (ibs) monitoring market size has grown rapidly in recent years. It will grow from $1.4 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to increasing prevalence of irritable bowel syndrome, growth of digital health platforms, rising adoption of telehealth services, expansion of smartphone-based health monitoring, availability of cloud-based patient data systems.

The remote irritable bowel syndrome (ibs) monitoring market size is expected to see rapid growth in the next few years. It will grow to $2.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to increasing demand for personalized gastrointestinal care, rising integration of remote diagnostics, expansion of value-based healthcare models, growing use of predictive analytics in disease management, increasing investments in digital therapeutics. Major trends in the forecast period include increasing use of AI-driven symptom analytics, rising adoption of mobile health monitoring platforms, growing integration of wearable ibs tracking devices, expansion of personalized treatment management tools, enhanced focus on patient engagement solutions.

The increasing prevalence of gastrointestinal disorders is expected to drive the growth of the remote irritable bowel syndrome (IBS) monitoring market going forward. Gastrointestinal disorders are conditions that disrupt the normal functioning of the digestive system, affecting digestion and bowel regulation. The rise in gastrointestinal disorders is primarily driven by poor dietary habits that negatively impact gut health, causing inflammation, bloating, and digestive discomfort. Remote IBS monitoring supports better disease management by enabling early identification of triggers, continuous tracking of symptoms, and personalized care, ultimately improving patient outcomes and quality of life. For instance, in February 2025, Crohn's & Colitis Australia, a national organization based in Australia, projected that the prevalence of inflammatory bowel disease (IBD) in Australia would rise from 20,511,881 cases in 2023 to 23,067,771 cases by 2030. Therefore, the growing prevalence of gastrointestinal disorders is propelling the growth of the remote IBS monitoring market.

Companies in the remote IBS monitoring market are focusing on white-label and co-branded service models to enhance remote monitoring capabilities. White-label or co-branded models allow healthcare providers to deliver established digital health solutions under their own brand, combining a trusted identity with proven technology for faster deployment, lower costs, and a seamless patient experience. For instance, in May 2024, Salvo Health, a US-based digital gastrointestinal care company, launched its first remote patient monitoring (RPM) program for gastrointestinal chronic conditions. The program covers IBS, GERD, dyspepsia, celiac disease, and SIBO, enabling GI practices to integrate remote monitoring with traditional care. Salvo provides GI providers with digital tools, clinical support, and home monitoring devices through its white-label and co-branded model, allowing tracking of heart rate variability (HRV) alongside patient diet, behavior, and symptoms to improve chronic care outcomes and practice efficiency.

In March 2024, Mahana Therapeutics, a US-based digital chronic condition management provider, acquired HiDoc Technologies GmbH for an undisclosed amount. This acquisition strengthens Mahana Therapeutics’ global reach in digital chronic disease management, expands its digestive health portfolio, and enhances patient outcomes through digital CBT programs. HiDoc Technologies GmbH, based in Germany, provides remote monitoring for IBS through its digital health application, Cara Care, and the partnership accelerates commercialization efforts in the US and Europe.

Major companies operating in the remote irritable bowel syndrome (ibs) monitoring market are Indegene, Vivante Health, Thryve Health, Heali AI Corp., Mahana Therapeutics Inc., metaMe Health Inc., Seed Health, Ayble Health, Oshi health, Salvo Health Inc., modifyhealth Inc., Food marble, nerva health, MyGiHealth, Sun Genomics, Dietahealth, Dige Health, Nori health, Sequenex, Bowelle.

North America was the largest region in the remote irritable bowel syndrome (IBS) monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the remote irritable bowel syndrome (ibs) monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the remote irritable bowel syndrome (ibs) monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the remote irritable bowel syndrome monitoring market by increasing costs of imported wearable sensors, mobile devices, data processing hardware, and secure cloud infrastructure components. Healthcare providers and digital health platforms in North America and Europe are most affected due to reliance on imported electronics, while Asia-Pacific faces higher costs for device manufacturing and exports. These tariffs are increasing platform deployment costs and slowing large-scale rollouts. At the same time, they are encouraging local device assembly, regional software development, and investment in domestic digital health ecosystems.

The remote irritable bowel syndrome (ibs) monitoring market research report is one of a series of new reports that provides remote irritable bowel syndrome (ibs) monitoring market statistics, including remote irritable bowel syndrome (ibs) monitoring industry global market size, regional shares, competitors with a remote irritable bowel syndrome (ibs) monitoring market share, detailed remote irritable bowel syndrome (ibs) monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the remote irritable bowel syndrome (ibs) monitoring industry. This remote irritable bowel syndrome (ibs) monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Remote irritable bowel syndrome (IBS) monitoring is a digital health solution that enables continuous tracking and management of IBS symptoms. It gathers real-time patient data, analyzes trends, and provides actionable insights to support proactive healthcare decisions. This approach improves patient engagement, allows timely interventions, and enhances overall symptom control and quality of life.

The main components of remote irritable bowel syndrome (IBS) monitoring include devices, software, and services. Devices encompass hardware tools and wearable technologies that track and record digestive health and IBS-related symptoms. The system is applied in areas such as diagnosis, symptom monitoring, treatment management, patient education, and more. Key end-users include hospitals and clinics, homecare providers, research institutes, and other healthcare stakeholders.

The remote irritable bowel syndrome (IBS) monitoring market consists of revenues earned by entities by providing services such as teleconsultations with gastroenterologists, dietary and lifestyle management guidance, digital health coaching, and patient data analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The remote irritable bowel syndrome (IBS) monitoring market also includes sales of wearable gut activity monitors, smart sensors, mobile monitoring devices, and connected health tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.